A Clinical tRial of Endobronchial Ultrasound for the Diagnosis of MEDiastinal lymphadenopathY (REMEDY)
Recruitment status was Active, not recruiting
Enlarged glands in the chest (mediastinal lymphadenopathy) is a common problem and may have a variety of different causes. In the past an operation (mediastinoscopy) was required to diagnose the glands. Endobronchial ultrasound (EBUS) is a new procedure that may be able to diagnose these glands without the need for mediastinoscopy. The REMEDY trial aims to examine whether EBUS can reduce the number of mediastinoscopies and healthcare costs in patients with enlarged glands in the chest.
Isolated Mediastinal Lymphadenopathy
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
|Official Title:||A Clinical tRial of Endobronchial Ultrasound for the Diagnosis of Isolated MEDiastinal lymphadenopathY (REMEDY)|
- Number of mediastinoscopies prevented and healthcare costs [ Time Frame: At diagnosis ] [ Designated as safety issue: No ]
- Length of hospital stay [ Time Frame: At diagnosis ] [ Designated as safety issue: No ]
- Sensitivity and false negative rate of endobronchial ultrasound [ Time Frame: At study completion ] [ Designated as safety issue: No ]
|Study Start Date:||July 2009|
|Estimated Study Completion Date:||October 2011|
|Primary Completion Date:||April 2011 (Final data collection date for primary outcome measure)|
All patients in the trial will undergo EBUS for the diagnosis of isolated mediastinal lymphadenopathy. If this investigation is negative then the patient will be referred for mediastinoscopy.
Endobronchial ultrasound guided transbronchial needle aspiration will be performed under conscious sedation and as an outpatient procedure. Additional bronchoscopy, transbronchial biopsies and bronchoalveolar lavage will be performed at the investigator's discretion.
Although the literature is replete with data on the utility of Endobronchial Ultrasound for lung cancer, there are very few data available on its role in the diagnosis of isolated mediastinal lymphadenopathy due to other causes such as sarcoid, tuberculosis or lymphoma. The REMEDY trial aims to evaluate the accuracy of EBUS in this setting and assess any reduction in the number of mediastinoscopies and healthcare costs.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00932854
|University College London Hospital|
|London, United Kingdom, WC1E 5DB|
|Principal Investigator:||Sam Janes, MD PhD||University College, London|
|Study Director:||Neal Navani, MD||Univeristy College London|